BIIB News 329.76 09/23/2014 04:31:26 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board

Sep 23, 2014 at 5:31 AM

Biogen Idec Inc (BIIB) 329.76 $BIIB

Most Big Cap 20 Stocks Near Entries, But Risks Exist
at Investor's Business Daily - Mon Sep 22, 6:05PM CDT
Most of the Big Cap 20 stocks are in buy ranges or forming bases. That's an unusually good trend that affords investors plenty of opportunities to deploy capital. But a sluggish market poses risks for any new purchases. For those willing to risk...

Isis Pharmaceuticals Up on $4M Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:40PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $4 million milestone payment from Achaogen (AKAO), following the initiation of a phase III study on plazomicin.

Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:20PM CDT
The European Commission has approved Gilead's (GILD) Zydelig for the treatment of CLL and FL.

Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.

3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...

Gilead's Zydelig Approved In EU; Imbruvica In Wings
at Investor's Business Daily - Fri Sep 19, 11:17AM CDT
The European Commission (EC) approved Gilead Sciences' (GILD) drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today. The EC approved the drug for...

Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:11AM CDT
Arena Pharmaceuticals, Inc. (ARNA) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.

Sobi expands Haemophilia development portfolio - elects to include potentially longer-acting Haemophilia A candidate in collaboration agreement with Biogen Idec
M2 - Fri Sep 19, 6:04AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company's collaboration with Biogen Idec. The XTEN technology is proprietary to Amunix Operating, Inc.. Biogen Idec and Amunix signed a worldwide license agreement in April 2014. Under the terms of Sobi and Biogen Idec's agreement, Sobi has the right to elect to include the rFVIIIFc-XTEN-vWF fusion molecule in the collaboration. Sobi is required to make a payment to Biogen Idec to include this program in the collaboration agreement.

Integra Poised on Impressive Duraseal Product Line, Solid Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:50PM CDT
On Jul 3, 2014, we issued an updated research report on Integra LifeSciences Holdings Corporation (IART).

Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:35PM CDT
Sanofi (SNY) announced that it has entered into an agreement with MyoKardia, Inc. to discover and develop targeted therapeutics for cardiomyopathies.

Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:10PM CDT
Alnylam Pharmaceuticals (ALNY) intends to file a clinical trial application for ALN-CC5 by year end.

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:51AM CDT
Repros Therapeutics Inc. (RPRX) saw a big move last session,continuing the recent downtrend for RPRX, as the stock is now down more than 11.5% in the past one-month time frame.

Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.

Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders
Business Wire - Wed Sep 17, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., has been invited to participate in upcoming panel discussions relating to innovation in Rx/Dx strategies and novel science developments in precision medicine.

Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks

Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:50PM CDT
Biogen Idec Inc. (BIIB) and partner AbbVie Inc. (ABBV) announced detailed positive results from the phase III study on Zinbryta.

SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 1.01% Loss
Comtex SmarTrend(R) - Mon Sep 15, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $315.71 to a high of $323.97. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $321.11 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nanjing Revives Cultural Legacy of Yangtze River

Breathing Life into an Ancient Waterway You'd think the Yangtze River story's as old as the hills—well, you're not wrong. But today, there's a fresh wind blowing down its waters. On November 10, scholars, cultural buffs, and a mixed bag of experts moseyed into Nanjing. They weren't just there to nibble dumplings and wax poetic; they were fixing to shed new light on the...

Bit Digital Shifts Focus: Q3 2026 Sees Strategic Moves

Bit Digital's Strategic Shakeup Ah, the digital gold rush is heating up again. Bit Digital, the outfit focused on Ethereum strategies and AI, dropped their financial results for Q3 2026. Picture a company at a strategic crossroads, shedding bitcoin mining baggage to grab hold of fresh opportunities in Ethereum staking and AI infrastructure. Bit Digital's earnings paint a...

LiuGong Pushes Sustainability at 2026 Dealer Conference

The Road to Green: LiuGong’s Ambitious Vision In a world where more heads are turning towards sustainability, LiuGong stepped up and showcased its green aspirations with flare at the 2026 Global Dealer Conference held from November 10 to 12 in Liuzhou, China. Over 2,000 attendees, ranging from dealers to customers, were in attendance to witness what seemed to be both a...

Porsche Atlanta North Under Group 1 Umbrella Post-Hennessy Deal

Porsche Atlanta North Joins Group 1's Fold If there's one thing you can count on in the automotive world, it's that someone is always wheeling and dealing. This time, it's Group 1 Automotive making waves, adding Porsche Atlanta North to its roster after snapping up Hennessy Automobile Companies' Atlanta-market dealerships. Group 1, a Houston-based powerhouse in the car...

Aristocrat's FY26 Delivers Momentum for FY27 Gains

FY26 Performance Worth Noting I'm telling you, Aristocrat is coming out swinging with their FY26 results—nothing short of mighty impressive. The company clocked a solid fiscal performance, registering a revenue growth spurt worth 4% in constant currency. Even while global markets are a swirling mess, they've found ways to take market share, proving they're more than...

O-I Glass Faces Class Action: What Investors Must Know

The Unsettling News for O-I Glass Investors Let me dive right into this mess about O-I Glass, Inc. (NYSE:OI). If you're tangled up in their stock, you probably felt that 15.01% nosedive in your portfolio recently. That's no minor blip. On July 28, 2026, as stocks were virtually put through the shredder, O-I Glass announced they had to cut down their financial guidance for...

ConnectDER Spurs a Battery Storage Revolution in CA

California's Energy Frontier with ConnectDER's IslandDER You know what's catching my eye these days? ConnectDER's IslandDER™ is shaking things up in sunny California, where the energy market's undergoing a seismic shift. Over a million hours logged, and a jaw-dropping 99.6% reliability rate—these numbers would make anyone sit up, especially with PG&E, SCE, SDGE, and...

Cleveland's Mayor Bibb: From AU Alumnus to Leader

For a guy who's juggled politics, climate action, and city administration, Mayor Justin Bibb revisiting the place where it all began—American University (AU)—is a story worth diving into. It's not every day you see a mayor take the stage at his alma mater, this time not as a student but as their December commencement speaker. Mayor Bibb's Journey from AU to City Hall...

Smirnoff and Broski Unleash Quirky Holiday Merch

Surprise in a Box: A Holiday Twist Who knew that a ukulele box would end up sparking more holiday joy than the instrument itself? Smirnoff Ice and social media sensation Brittany Broski are giving us a holiday roll-out that takes a good look at the absurd and runs with it. Instead of strings and melodies, you open that box to find a Smirnoff Ice bottle ready to chill your...

Align's Innovative Transporter Revolutionizes Engine Assembly

Align's Game-Changer in Engine Manufacturing Let's face it, the world of heavy-duty equipment isn't always filled with breakthroughs. But every once in a while, a game-changer rolls off the line, and that's what's happening with Align Production Systems. They've crafted a custom omnidirectional transporter that does more than just move bulky engine assemblies; it...